JPMorgan's price target cut reflects near-term caution around the GLP-1 pivot, with Hims & Hers retooling its U.S. weight loss offering away from compounded versions toward branded alternatives as branded supply has stabilized and compounded products have come off the FDA shortage list. Compounded GLP-1s carried higher margins, and the handoff is creating reporting noise.
Barclays analyst Emily Field raised Eli Lilly's price target to $1,400, emphasizing the strong momentum of tirzepatide, which is central to the company's growth strategy. The recent earnings report showcased a 56% year-over-year revenue increase, driven by significant contributions from Mounjaro and Zepbound, indicating robust demand and market expansion.
AbbVie reported Q1 2026 revenue of $15 billion, beating the $14.72 billion consensus and growing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 million IPR&D charge clipped $0.41 per share.
Marriott's luxury-heavy portfolio looks insulated from inflation pinching price-sensitive travelers, yet Susquehanna's Neutral stance signals valuation is doing the heavy lifting.
Northcoast initiated coverage of Hertz stock with a Sell rating and a $5 price target, placing it well below where shares have traded since the rally accelerated in early April.
Wedbush's core argument centers on vertical integration as the most underappreciated dimension of the MP Materials story. The cross-pollination between Mountain Pass and Independence creates cost and quality advantages that flow in both directions, meaning the mine makes the magnet facility better, and the magnet facility makes the mine more valuable.
UBS initiated coverage on LPL Financial with a Buy rating and a price target of $380, suggesting a measured but constructive first-impression thesis amid a challenging market environment.
